1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8
Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
News, Material Contracts
Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Annual Report to Security Holders
FDA Issues Complete Response Letter for Etripamil for PSVT
Q2
Q1
FY 2024
Q3
FY 2023 amended
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload